The NOSTRA-Feasibility Study (NCT04118192) is looking at US-guided tumor core biopsy in women with ER negative, HER2-positive early-stage disease who undergo neoadjuvant chemotherapy plus dual-targeted anti-Her2 treatment to observe the FNR. Here, ERBB2 is linked to neoplasm.